<DOC>
	<DOC>NCT01483911</DOC>
	<brief_summary>ALX-0171 is a Nanobody directed against the human respiratory syncytial virus (RSV). The purpose of this first-in-man study is to determine the safety, tolerability and pharmacokinetics (PK) of ALX-0171 after single and multiple pulmonary administrations in healthy male volunteers.</brief_summary>
	<brief_title>ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Nonsmoking healthy male volunteers, aged 1855 years Good health condition, as determined by medical history, physical examination and clinical laboratory testing Forced expiratory volume in 1 second (FEV1) ≥ 90% of predicted value Diffusing capacity of the lung for CO (DLCO) ≥ 85% of predicted value Normal chest XRay (anteroposterior and lateral view) Minimum weight of 70.0 kg, minimum height of 1m70, body mass index between 18.0 and 30.0 kg/m² Current smokers, or exsmokers abstinent from tobacco for less than one year History or presence of atopy or pulmonary nonspecific hyperreactivity Positive bronchial challenge test Symptomatic viral infection, or suspicion thereof (including rhinitis) in last 14 days prior to dosing Signs of active pulmonary infection or other inflammatory conditions, even in the absence of febrile episodes, in the last 14 days prior to dosing</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>